Direct thrombin inhibitor use during percutaneous coronary intervention

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 3, 2005, Pages 270-279

  Kokolis, Spyros ^a   Clark, Luther T ^a   Cavusoglu, Erdal ^a   Marmur, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Bivalirudin; Percutaneous coronary intervention

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DALTEPARIN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTICOAGULANTS; HEPARIN; HUMANS; THROMBIN;

EID: 14744269022     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000154373.80659.38     Document Type: Review

References (79)

1. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 1998;114:489-510.
2. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth. 2002;49:S11-S25.
3. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25(suppl 3):5-16.
4. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost. 1996;22:117-124.
5. Rosenberg RD, Oosta GM, Jordan RE, et al. The interaction of heparin with thrombin and antithrombin. Biochem Biophys Res Commun. 1980;96:1200-1208.
6. Ofosu FA, Barrowcliffe TW. Mechanisms of action of low molecular weight heparins and heparinoids. In: Hirsh J, ed. Antithrombofic Therapy, Baillieres Clinical Haematology, vol 3. London, UK: Bailliere Tindall, 1990, pp 505-529.
7. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: JB Lippincott, 1994, pp 837-860.
8. Weite JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
9. Anderson W, Harthill JE. Molecular weight dependence of heparin anti-factor Xa activity: influence of method. Thromb Res. 1981;21:557-564.
10. Danielsson A, Raub E, Lindahl U, et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986;261:15467-15473.
11. Rosenberg RD, Jordan RE, Favreau LV, et al. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 1979;86:1319-1324.
12. Jordan RE, Favreau LV, Braswell EH, et al. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem. 1982;257:400-406.
13. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97:544-552.
14. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116:178-186.
15. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:12P-18P.
16. Fenton JW, Villanueva GB, Ofosu FA, et al. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis. 1991;21(suppl 1):27-31.
17. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 1986;25:4622-4628.
18. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29:7095-7101.
19. Bursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503-516.
20. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
21. Robson R, White H, Aylward P, et al. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002;71:433-439.
22. Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis. 1996;7:438-448.
23. Maraganore JM. Hirudin and Hirulog: Advances in antithrombotic therapy. Perspect Drug Discov Des. 1993;1:461-478.
24. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 1986;25:4622-4628.
25. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 2001;103:1479-1484.
26. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation. 2001;103:643-650.
27. Greinacher A. Recombinant hirudin for treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, 2000, pp 313-338.
28. Stringer K, Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother. 1992;26:1535-1540.
29. Potzsch B, Hund S, Madlener K, et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res. 1997;86:373-383.
30. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 1995;50:20-25.
31. Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 1999;100:1528-1532.
32. Agatroban Injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2003.
33. Dager WE, Vondracek TG, McIntosh BA, et al. Ximelagatran: an oral direct thrombin inhibitor. Ann Pharmacother. 2004;38:1881-1896.
34. Eriksson UG, Bredberg U, Hoffman KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003;31:294-305.
35. Gustafsson D, Nystrom JE, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171-181.
36. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
37. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial. Circulation. 1999;100:1593-1601.
38. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol. 1998;82:9L-24L.
39. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction - the ASSENT Plus study. Eur Heart J. 2003;24:897-908.
40. Wallentin L, Husted S, Kontny F, et al. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol. 1997;80:61E-63E.
41. James S, Armstrong P, Califf R, et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J. 2002;23:1538-1545.
42. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med. 1997;337:447-452.
43. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658-663.
44. Ferguson JJ, Antman EM, Bates ER, et al. The use of enoxaparin and GPIIb/IIIa antagonists in acute coronary syndromes. Final results of the NICE 3 study. [abstract] J Am Coll Cardiol. 2001;37(suppl 2):1253-1297.
45. Kereiakes DJ, Grines C, Fry E, et al. The NICE 1 and NICE 4 Investigators, National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272-278.
46. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. 2003;41:20-25.
47. Arjomand H, Surabhi SK, Cohen M. Unfractionated versus fractionated heparin for percutaneous coronary intervention. Curr Cardiol Rep. 2002;4:327-333.
48. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92.
49. Esprit Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
50. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.
51. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105S-111S.
52. Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002;143:585-593.
53. Kleiman NS, Lincoff AM, Sapp SK, et al. Pharmacodynamics of a direct thrombin inhibitor combined with a GP IIb-IIIa antagonist: First experience in humans. [abstract] Circulation. 1999;100(suppl 18):1328.
54. Kleiman NS, Lincoff AM, Harrington RA, et al. Antithrombin, anti-platelet therapy or both during PCI: A preliminary randomized trial. J Am Coll Cardiol. 2001;37(suppl 2):1648.
55. Lincoff AM, Bittl JA, Kleiman NS, et al for the REPLACE Investigators. The REPLACE 1 Trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP Ilb/IIIa blockade. [abstract] J Am Coll Cardiol. 2002;39(suppl 5):16A.
56. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-853.
57. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
58. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol. 2000;12(suppl F):14F-9.
59. Campbell KR, Wildermann N, Janning C, et al for the ATBAT Investigators. Bivalirudin during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia: interim results of the ATBAT Trial. [abstract] Am J Cardiol. 2000;86(suppl 8):73i-74i.
60. Bhatt DL, Cho L, Lincoff AM, et al. Reduction in percutaneous coronary intervention-related bleeding with bivalirudin is particularly striking in women. J Am Coll Cardiol. 2002;39(suppl 5):1053-1054.
61. Aguirre FV, Gill JB. Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol. 2002;14(suppl B):48B-54B.
62. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2). Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429-438.
63. Eikelboom J, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to assess strategies for ischemic syndromes (OASIS-2) study. Circulation. 2001;103:643-650.
64. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995;333:757-763.
65. Matthai WH. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25(Suppl 1):57-60.
66. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
67. Lewis BE, Mathai W, Grassman ED. Results of a phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia. Circulation. 1997;96(Suppl):I-217. Abstract.
68. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis. 2001;12:141-149.
69. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
70. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
71. Moscucci M, Share D, Kline-Rogers E, et al. The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality improvement initiative in percutaneous coronary interventions. J Interv Cardiol. 2002;15:381-386.
72. Ahmed WH, Piana RN, Bittl JA. Does bleeding cause ischemic events after coronary angioplasty [abstract]? Circulation. 1996;94(Suppl 8):376.
73. Bittl J. Switching from heparin to a thrombin-specific anticoagulant (bivalirudin) for PTCA in unstable angina patients reduces major clinical events. [abstract] Circulation. 2000;102(18Suppl):813.
74. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors. J Clin Invest. 1990;86:385-391.
75. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
76. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invasive Cardiol. 2000;12(Suppl A):1A-5A.
77. Adamian M, Mehran R, Mintz GS, et al. Safety and feasibility of direct thrombin inhibitor bivalirudin during percutaneous coronary interventions in patients with chronic renal failure. Results of the pilot study. [abstract] Am J Cardiol. 2002;90(suppl 6):162H.
78. Adamian M, Farkouh M, Mehran R, et al. A matched comparison of safety and feasibility of bivalirudin in patients with diabetes mellitus during percutaneous coronary interventions. [abstract] Am J Cardiol. 2002;90 (suppl 6):161H.
79. Cho L, Chew DP, Moliterno DJ, et al. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. Am J Cardiol. 2003;91:742-743.